ArticleMedicine2025
Esophago-tracheobronchial fistula induced by anlotinib: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAnlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) that targets tumor angiogenesis and proliferation signals, demonstrating significant antiangiogenic effects. It is used as a third-line treatment for refractory advanced non-small cell lung cancer. PATIENT CONCERNS: An elderly male patient with lung squamous cell carcinoma, who was intolerant to chemotherapy, received anlotinib for antitumor treatment and experienced choking when eating and drinking. DIAGNOSES: Pulmonary computed tomography revealed an irregular cavity adjacent to the mediastinum in the right lung, measuring ~75 mm × 49 mm. Endoscopic examination combined with gastroscopy and tracheoscopy under general anesthesia showed erosion of the carina, absence of the right side, and an ~3-cm-long, oval-shaped esophagotracheal fistula located 26 to 29 cm from the incisors.
interventionsA partially covered esophageal stent was placed endoscopically. OUTCOMES: During the 6-month follow-up period, the patient's esophagotracheal fistula narrowed, and he no longer experienced choking while eating or drinking. LESSONS: The incidence of adverse reactions to anlotinib is relatively low, and esophago-tracheobronchial fistula caused by it is even rarer. When using anlotinib to treat non-small cell lung cancer, clinicians need to monitor changes in patients' symptoms closely. If symptoms of choking when eating and drinking occur, pulmonary computed tomography should be promptly repeated to detect signs of esophago-tracheobronchial fistula early and intervene promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.